


UK NEQAS

Leucocyte Immunophenotyping



New Information for 2027–2028

EQA/PT Programmes for
Molecular Haemato-Oncology

SAVE THE DATE: 14TH JUNE 2027

UK NEQAS LI SCIENTIFIC MEETING, SHEFFIELD - *REGISTRATION OPENING 2027*

EQAInternational
Working in partnership with UK NEQAS LI



www.ukneqasli.co.uk

New Information for 2027–2028

EQA/PT Programmes for Molecular Haemato-Oncology

Report Assessment

As a response to participant feedback, we will be providing optional report assessments in 2027–2028. Participants will be able to upload a report to the UK NEQAS LI website for assessment. This will initially be available in the **Myeloid Gene Panels** and **Myeloproliferative Neoplasm Diagnostic Testing** programmes. We hope to roll this out to additional programmes in future years. Reports will be assessed for clerical, analytical and interpretive accuracy. This will not be formally performance monitored initially.

Myeloproliferative Neoplasms Diagnostic Testing Additional Marker Accreditation

Building on the existing UKAS accredited qualitative JAK2 p.(Val617Phe) component of the Myeloproliferative Neoplasms Diagnostic Testing programme, UK NEQAS LI is now UKAS accredited for the JAK2 exon 12, CALR exon 9 and MPL exon 10 markers. The additional markers will now be subject to qualitative performance monitoring, expanding the scope of the programme. Testing for all four markers is not mandatory if such testing is not offered by the participating laboratory, with performance monitoring subject to the laboratory's testing repertoire.

In addition, UK NEQAS LI are now accredited to provide quantitative JAK2 p.(Val617Phe) performance monitoring for participants that return quantitative results for samples in which the variant has been detected. This will be optional and independent of the performance monitoring of qualitative results.

Lymphoplasmacytic Lymphoma / Waldenström Macroglobulinaemia Automation

Work is underway to automate data entry and reporting for the Lymphoplasmacytic Lymphoma / Waldenström Macroglobulinaemia programme.

The current process relies on external data submission. Automation will enable participant data entry via the Participant Hub and support automated analysis, reporting, and performance monitoring.

Minor BCR::ABL1 Quantification Data Entry

Currently, data entry for the minor BCR::ABL1 quantification programme is primarily designed to capture information from participants using RT-PCR. As technologies and methodological approaches to testing evolve, data entry needs to evolve with them.

Changes are therefore being made to better capture and accommodate data submitted by participants using digital PCR and Cepheid methodologies.

SEE WEBSITE FOR FULL INFORMATION ON ALL OF THE ABOVE CHANGES

Should you wish to participate in any of the above programmes please contact:

UK NEQAS LI
Pegasus House
4th Floor Suite
463a Glossop Road
Sheffield S10 2QD
United Kingdom

Tel: +44 (0)114 2673600

Fax: +44 (0)114 2673601

email: admin@ukneqasli.co.uk

www.ukneqasli.co.uk

Please note that if your participation with UK NEQAS LI is via a non-UK distributor you should contact them directly for details of how to register. If you are enquiring from outside of the UK your registration will be managed by EQA International Ltd.